CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 98 enrolled
Drug / intervention
Lactobacillus rhamnosus GG (LGG) Probiotic +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04529980
NCT04529980N/ACompleted

Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis: Prospective Controlled-Comparison Trial

Children's Health·interventional·Posted Aug 28, 2020·Updated Aug 13, 2024

In Brief

A clinical study evaluating Lactobacillus rhamnosus GG (LGG) Probiotic and Placebo for Appendicitis and Appendicitis; Perforation. Completed, enrolled 98 participants across 1 site.

Detailed Summary

To determine the effectiveness of the use of probiotics in patients with a diagnosis of complicated appendicitis on antibiotic associated diarrhea (AAD). Probiotics are defined as live microbial organisms that when administered in sufficient amounts, can provide a protective benefit to the individual patient. The use of probiotics in a pediatric population exposed to antibiotics and gastrointestinal surgery such as an appendectomy may provide a protective effect and prevent antibiotic associated diarrhea (ADD)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 28, 2020
Enrollment StartSep 8, 2020
Primary CompletionFeb 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.8 years ago

Interventions

Lactobacillus rhamnosus GG (LGG) Probioticdietary

Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health.

Placebodietary

Placebo